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Rotational atherectomy in the era of drug-eluting stentsAtherosclerosis is one of the most significant underlying
problems that can affect patients with cardiovascular disease.
In the most serious situations, this condition affects blood
supply to the heart or brain, resulting in heart attack, stroke, or
sudden cardiac death. In 1977, Andreas Gruentzig performed
the first percutaneous transluminal coronary angioplasty
(PTCA), a less invasive method for treating obstructive coro-
nary artery disease. However, soon after Gruentzig showed
that PTCA was viable, the procedure was only undertaken
when focal noncalcified lesions in the proximal coronary
arteries were targeted, in an attempt to avoid serious compli-
cations such as abrupt vessel closure from intimal dissection,
elastic recoil of the artery, and restenosis. In addition to these
complications, the inability to dilate certain types of coronary
lesions, particularly heavily calcified lesions, is another major
limitation of PTCA.
Before the bare metal stent (BMS) era, the search for ther-
apeutic strategies to overcome these PTCA limitations was
based on animal studies, which showed that severe injury
induced a stronger healing response of the treated vessel.1
Angiographic analyses have revealed that the degree of late
restenosis was directly proportional to the acute gain of luminal
diameter achieved from angioplasty treatment, and that the
proportion between late loss and acute gain was consistent for
different interventional devices.2 Based on these observations,
the mechanical approach to plaque excision was supposed to
lower the restenosis rate and improve clinical outcomes.
Percutaneous coronary rotational atherectomy (PTCRA) was
developed in the late 1980s as a debulking device used to
facilitate the removal of plaque. Compared to arterial stretching
and plaque fracture as seen in PTCA, PTCRA increases the
luminal diameter by debulking atherosclerotic plaques with the
aid of an abrasive diamond-coated burr.
Using routine atheroablation during percutaneous coronary
intervention (PCI) is theoretically beneficial; however, clinical
evidence from randomized control trials challenges this
hypothesis. The rotational atherectomy and conventional bal-
loon angioplasty (DART) comparison study, which has been
widely cited for its use of PTCRA in noncomplex lesions in
smaller coronary arteries (<3.0 mm), did not demonstrate a
different procedural success rate or postprocedure residual
stenosis rate between PTCA using adjunctive PTCRA and
PTCA alone at 12 months.3 For complex coronary artery
lesions, the excimer laser, rotational atherectomy, and balloon1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.12.001angioplasty comparison (ERBAC) study, in which >70% of
lesions were classified as American Heart Association/
American College of Cardiology type B2 or C, revealed that
although PTCRA had a higher initial procedural success rate
(89% vs. 80%). It also showed a significantly increased target
lesion restenosis (TLR) rate at 1 year (57% vs. 47%).4 In
addition, the comparison of balloon angioplasty versus rota-
tional atherectomy in complex coronary lesions (COBRA)
study, which specifically enrolled patients with heavily calci-
fied and complex lesions, also showed better initial procedural
success with PTCRA (85% vs. 78%) but did not show any
difference in restenosis rates, TLR rates, or symptomatic
outcomes at 6 months.5
In the BMS era, the problems of coronary dissection and
elastic recoil after PTCA have been solved by using coronary
stenting. However, in-stent restenosis (ISR) evolved as a major
issue, especially for the stenting of complex lesions such as
calcified lesions, long lesions, lesions with small vessel diam-
eters, bifurcation lesions, chronic total occlusions, and saphe-
nous vein grafts. The reported ISR rate of BMS was 16e44%.
Is there any role of PTCRA in lowering ISR by debulking
stenting, the so-called rotastenting? In the effects of debulking
on restenosis (EDRES) study, compared with stenting alone,
rotastenting did not improve final stent diameter, but reduced
binary restenosis (BR) rates at 6 months.6 The debulking prior
to stenting (SPORT) study, a larger trial than the EDRES trial,
revealed a better procedural success rate and posttreatment
minimal luminal diameter in the rotastenting group; however,
no differences were observed in the rates of in-hospital major
adverse cardiac event (MACE), BR, or TLR rates at the
6-month follow-up.7
In the absence of beneficial effects on ISR prevention, is
there any role for PTCRA in ISR treatment? The atherectomy
for treatment of diffuse in-stent restenosis trial (ARTIST)
study randomized ISR patients to receive PTCA alone or
PTCRA with adjunctive PTCA; however, no difference was
observed in acute procedural success. At 6 months, the
PTCRA group had an even higher restenosis rate and worse
event-free survival rate.8 In contrast, the randomized trial of
rotational atherectomy versus balloon angioplasty for diffuse
in-stent restenosis (ROSTER) study showed beneficial effects
in the PTCRA group, which had a lower TLR rate and lower
repeat stent use at 12 months.9 Because the effects of PTCRA
on ISR were inconsistent, the use of PTCRA is currentlyhinese Medical Association. All rights reserved.
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success rate of subsequent angioplasty, especially in compli-
cated calcified lesions.10
In the beginning of the third millennium, the conundrum of
the high postprocedure restenosis rate has been largely elim-
inated by the advent of the drug-eluting stent (DES). Over the
past decade, the incidence of DES failure, defined as ISR
requiring target vessel revascularization (TVR), has been
approximately 5e10%. Nevertheless, heavily calcified lesions
remain a major technical challenge to most interventionists.
First, compared with BMS, DES has a twofold higher failure
rate of successful deployment in calcified lesions.11 Second,
Wiemer et al demonstrated that vigorous manipulation of
DES through calcified lesions can damage and crack the
DES polymer, which may increase the vascular inflammatory
response.12,13 Third, suboptimal deployment of DES in these
complex lesions could increase the risk of stent thrombosis.14
To overcome these problems, adequate lesion preparation and
modification by PTCRA are imperative for a successful DES
deployment in severely tortuous and calcified coronary
lesions.
In the current issue of the Journal of the Chinese Medical
Association, Chiang et al15 report the retrospective long-term
clinical outcomes of rota-DES for heavily calcified coronary
lesions in real-world practice from a single-center registry.
Although similar rota-DES reports have been published in the
literature, Chiang et al’s report presents several unique points.
This study had the oldest patients with the highest percentage
of chronic renal insufficiency, diseased coronary vessels, high
coronary artery calcification scores, and high bailout PTCRA
rates. Nevertheless, a reasonable procedural success rate and a
good long-term outcome were achieved. The study’s MACE/
TLR/TVR rates were also compatible with those of previously
published reports. Therefore, PTCRA is again a feasible
adjunctive therapy before DES implantation, especially in
heavily calcified coronary lesions.
However, some unanswered questions remain concerning
the use of PTCRA in the DES era. For example, does the
severe extent of calcification along with crossable and
expansible stenotic lesion indicate that PTCRA is necessary
before DES implantation? Does the use of a different DES
polymer coating affect long-term outcome?12 What are the
roles of intravascular ultrasonography for rota-DES in calci-
fied lesion preparation and the evaluation of stent expansion
adequacy? To precisely define the roles of PTCRA in the DES
era, further large-scale, prospective randomized studies are
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